Dear Colleagues,

Hepatocellular carcinoma (HCC) is the most common hepatic malignancy and one of the top five leading cause for cancer-related deaths worldwide. Despite ongoing efforts and developments in terms of diagnostic techniques and therapeutic strategies, the overall prognosis for patients with HCC remains dismal. As such, the golden rule to gain the greatest benefit remains early diagnosis followed by curative treatment for HCC. However, the majority of patients are diagnosed in the advanced stages of HCC leading to ineligible for potential curative treatments that require other effective therapies. Along with the advancement of oncology, numerous molecular targeted agents including multikinase inhibitors, antiangiogenic monoclonal antibodies, and immunotherapeutic regimens are getting more attention to be an effective treatment for advanced HCC.

Therefore, we invite authors to contribute original research or review article that will stimulate the investigation of HCC. In this special issue, we particularly take an interest in manuscript that investigate and discuss the current status and limitation of molecular mechanisms and therapies of HCC. Moreover, any innovation thought that could potentially facilitate the progress of this field in terms of pathogenesis, treatments and prevention of cancer recurrence are encouraged. Basic studies or translational studies including molecular mechanism and/or novel therapeutic strategy from real practice are most welcome.

Dr. Kun-Ming Chan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• hepatocellular carcinoma
• molecular mechanism
• pathogenesis
• antiagiogensis
• immunotherapy
• novel therapy